Kymera IPO Presentation Deck

V FIBROSIS STAT3 Degrader Active in T Cell Activation Preclinical In Vivo Model Multiple Sclerosis Model KYMERA shown in Solid Tumors Autoimmune Fibrosis * A preclinical model of experimental autoimmune encephalomyelitis (T cell activation) was used to evaluate STAT3 degradation Kymera STAT3 Degrader completely prevented onset of the disease in mice % Incidence of Disease 100 75 50 25 0 10 15 Days 20 Vehicle Dexamethasone, PO, QD STAT3 Degrader 10 mg/kg STAT3 Degrader 25 mg/kg Normal (non-immunized) 25

View entire presentation